secondary outcome measures included the neuropsychiatric inventory (npi), the alzheimer's disease cooperative study - activities of daily living (adcs-adl) scale, levels of aβ1-40 and aβ1-42 in plasma and levels of aβ1-42, t-tau, p-tau181 and f2-isoprostanes in cerebrospinal fluid.